Recent Updates
Recently added Catalysts

PRGN-2012

Phase 1

Recurrent Respiratory Papillomatosis | Small molecule | Infectious Disease |Precigen, Inc.|Last Updated: Jun 11, 2025

Target and mechanism

ModalitySmall molecule

Also known as PRGN-2012 - Phase I; Dose Level 1, PRGN-2012- Phase I; Dose Level 1, PRGN-2012 - Phase II; Dose Level 2, PRGN-2012- Phase II; Dose Level 2

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

CONTROLLED
Total Trials1
Total Enrollment38

FDA Designations

BREAKTHROUGH_THERAPYORPHAN_DRUGACCELERATED_APPROVALPRIORITY_REVIEW

Clinical trial landscape

PRGN-2012 · 1 trial · 3 indications

Phase 1 1
NCT04724980Adjuvant PRGN-2012 in Adult Patients With Recurrent Respiratory PapillomatosisRecurrent Respiratory Papillomatosis
ACTIVE NOT_RECRUITING38 Analytics
PHASE1ACTIVE NOT_RECRUITING
Adjuvant PRGN-2012 in Adult Patients With Recurrent Respiratory Papillomatosis
Recurrent Respiratory PapillomatosisUnlock trial analytics

Study Endpoints

Primary Endpoints

Determine the percentage of subjects with a complete response following treatment with PRGN-2012
1 year

A complete response is defined as no requirement for surgical intervention in the 12 months after treatment

Determine the incidence of dose limiting toxicities to evaluate safety and identify RP2D of PRGN-2012
28 days

The incidence of dose limiting toxicities in Phase 1 will be reported per dose level. The dose level at which less than or equal to 1 out of 6 patients experience DLT will be identified as a RP2D.

Secondary Endpoints

Safety of PRGN 2012 at RP2D
1 year
Immune Responses
1 year
Change in RRP Staging Assessment Scores Over Time
1 year
Unlock Study Endpoints

Study Design & Arms

AllocationNON_RANDOMIZED
MaskingNONE
ModelSEQUENTIAL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
Phase I; Dose Level 1EXPERIMENTALA standard dose escalation design was used to evaluate PRGN-2012 at a dose level of 1 × 10\^11
Phase I; Dose Level 2EXPERIMENTALA standard dose escalation design was used to evaluate PRGN-2012 at a dose level of 5 × 10\^11
Phase II; Dose Level 2EXPERIMENTALA dose of 5 x 10\^11 PU was established as the RP2D, and the Phase 2 portion was implemented. The Phase 2 portion is designed as a dose expansion study, where patients were treated at the RP2D to evaluate the safety and efficacy of PRGN-2012.

Interventions

NameTypeDescription
PRGN-2012 - Phase I; Dose Level 1DRUGIn Phase 1, dose level 1 of the clinical trial, PRGN-2012 is administered at 1 × 10\^11 particle units as adjuvant therapy prior to standard debulking surgery.
PRGN-2012 - Phase I; Dose Level 2DRUGIn Phase 1, dose level 2 of the clinical trial, PRGN-2012 is administered at 5 × 10\^11 particle units as adjuvant therapy prior to standard debulking surgery.
PRGN-2012 - Phase II; Dose Level 2DRUGThe Phase 2 portion is designed as a dose expansion study where patients are treated at the RP2D of 5 x 10\^11 PU.
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to N/A
SexALL
Healthy VolunteersNo
Study Sites1

INCLUSION CRITERIA: * Age 18 years and older * Clinical diagnosis of RRP * Histological diagnosis of papilloma confirmed by pathology report from a CLIA-certified (or comparable) laboratory * Presence of laryngotracheal papillomas with or without pulmonary RRP * A history of 3 or more interv...

Countries:United States
Unlock Eligibility Criteria